MD STRATEGIES
RESEARCH CENTERS

CURRICULUM VITAE

SIGNATURE:	Samuel Etchie	**DATE:**	01-FEB-2019
NAME: **TITLE:**	Samuel O.T Etchie, MD Principal Investigator	**DATE UPDATED:**	Feb. 2019

RESEARCH SITE NAME/ ADDRESS:

Main Office: MD Strategies Research Centers 6280 Jackson Drive, Suite 8 San Diego, California 92119	Office: 619-464-1607 Fax: 619-303-0559 Email: dretchie@mdsrsandiego.com

EDUCATION/TRAINING:

INSTITUTION AND LOCATION	DEGREE *(if applicable)*	YEAR(s)	FIELD OF STUDY
University of California, Los Angeles, CA	Fellowship	1999	Forensic Psychiatry
University of California, San Diego San Diego, CA	Residency	1998	Chief Resident (Psychiatry)
University of California, San Diego San Diego, CA	Residency	1997	Psychiatry
Texas Tech University El Paso, Texas	Internship	1995	Anesthesiology
University of Ibadan, Oshun State, Nigeria College of Medicine	Bachelor	1992	Medicine

BOARD CERTIFIED:

BOARD CERTIFIED/ELIGIBLE	YEAR(s)	SPECIALTY
American Board of Psychiatry and Neurology Board Certification	2014-2024	Psychiatry
Board Eligible, American Academy of Psychiatry and The Law	N/A	Psychiatry

POSITIONS AND EMPLOYMENT:

2018- Present	Investigator, MD Strategies Research Centers, San Diego, CA
1999-Present	Psychiatrist, Samuel Etchie, MD, Inc, La Mesa, CA
2001- Present	Member, Pharmacy and Therapeutics Committee, Alvarado Parkway Institute/ Behavioral Health Systems, La Mesa, CA
2001-2004	Principal Investigator, SDCCR, San Diego CA
1998-2001	Sub-Investigator, Synergy Clinical Research Center, National City, CA
2011- 2013	Chief of Staff, Elect, Promise Hospital, San Diego, CA
2001-2013	Chairman, Peer Review Committee, Villa View Community Hospital/ Promise Hospital, San Diego, CA
2001- 2005	Chief of Psychiatry, Promise Hospital, San Diego, CA
2001-2005	Member, Scripps Mercy Hospital Institutional Review Board (IRB), San Diego, CA

CERTIFICATION AND ASSOCIATIONS

San Diego Society of Psychiatry Physicians
American Psychiatric Association
American Medical Association
San Diego County Medical Society

LICENSURE:

California Board of Medical Examiners, Physicians and Surgeons
Federal Licensing Examination (FLEX)
Foreign Medical Graduate Exam Med. Sciences (FMGEMS}
Education Commission for Foreign Medical Graduates

CLINICAL RESEARCH EXPERIENCE:

Sub investigator:

Abbott: A Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Safety and Efficacy of ABT-XXX, Duloxetine and Placebo in Subjects with Diabetic Neuropathic Pain

Abbott: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of XXX-XXX in the Treatment of Cognitive Deficits in Schizophrenia (CDS)

Alexza: A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multi-Dose Efficacy and Safety Study of Staccato® Loxapine for Inhalation in Schizophrenic Patients with Agitation

Anchen: A Two-Period, Two-Treatment, Open Label, Two-Way Steady-State Crossover Bioequivalence Study of Quetiapine Fumarate Extended Release 400 mg Tablets under Fasting Conditions in Patients

Arena: A 52-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Safety and Efficacy of Lorcaserin Hydrochloride in Overweight and Obese Patients with Type 2 Diabetes Mellitus Managed with Oral Hypoglycemic Agent(s)

Baxter: A Randomized, Double-Blind, Placebo-Controlled, Two Dose-Arm, Parallel Study of the Safety and Effectiveness of Immune Globulin Intravenous (Human), 10% (IGIV 10%) for the Treatment of Mild-to-Moderate Alzheimer's Disease

Boehringer Ingelheim: A randomized, double-blind, placebo-controlled parallel group efficacy and safety study of XX XXXX (5mg administered orally once daily) over 18 weeks in Type 2 diabetic patients with insufficient glycaemic control (HbA1c 7.0-10%) despite background therapy with a sulfonylurea drug.

Braincells: A Double-Blind, Placebo-Controlled Study of Buspirone in Combination with Melatonin in Patients with Major Depressive Disorder (MDD)

Bristol Myers Squibb: A Double-Blind, Placebo-Controlled Study of Aripiprazole Adjunctive to Antidepressant Therapy (ADT) among Outpatients with Major Depressive Disorder Who have responded Inadequately to Prior ADT

Chorus, Lilly: An Efficacy and Dose-Finding, Proof of Concept Study of LYXXXXXXX for the Acute Treatment of Migraine Headache Using an Adaptive Design

Corcept: A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of CORLUX (Mifepristone) Vs. Placebo in the Treatment of Psychotic Symptoms in Patients with Major Depressive Disorder with Psychotic Features

Elan: A Phase II, Multicenter, Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Efficacy and Safety Trial of Bapineuzumab (XXX XXX, XXXXXXXXX) in Patients with Mild to Moderate Alzheimer's Disease who are Apolipoprotein ε4 Non-Carriers.

Forest: A Double-Blind Placebo-Controlled Study of XXX-XXX in Bipolar Depression.

Forest: A Double-Blind Placebo-Controlled Study of XXX-XXX as adjunctive therapy in Major Depressive Disorder.

Eli Lilly: "Maintenance of Response After Open-Label Treatment with Atomoxetine Hydrochloride in Adult Outpatients with Attention-Deficit/Hyperactivity Disorder (ADHD): A Placebo-Controlled, Randomized Withdrawal Study"

GlaxoSmithKline: A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed Dose Study Evaluating the Effciacy and Saftey of Orvepitan in Subjects with Major Depressive

GSK: A randomized double-blind, placebo controlled, parallel group study to evaluate the cognitive enhancing effect of XXXXXXXXX in stable patients with schizophrenia.

Johnson & Johnson: A Single-Dose, Open-Label, Randomized, Parallel-Group Study to Assess the Pharmacokinetics, Safety, and Tolerability of a Paliperidone Palmitate 3-Month Formulation in Subjects With Schizophrenia.

Lundbeck: A randomised, double-blind, parallel-group, flexible-dose study exploring the neurocognitive effect of sertindole versus quetiapine in patients with schizophrenia using the MATRICS Consensus Cognitive Battery (MCCB).

Merck: A Phase IIb, Multicenter, Randomized, Double-Blind, Placebo-Controlled, 2-Period Adaptive Crossover Polysomnography Study to Evaluate the Safety and Efficacy of XX-XXXX in Patients with Primary Insomnia.

Novartis: A 12-Week, Randomized, Multicenter, Open-Label, iloperdone, (12-24mg/day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole (i-FANS) (IND 36,827 – Phase IV Study)

Orexigen: A Proof-of-Concept, Multicenter, Randomized, Double-Blind, Parallel Study of Naltrexone Sustained Release (SR) and/or Fluoxetine Therapy in the Treatment of Subjects with Obsessive-Compulsive Disorder (OCD)

Orexigen: A Proof of Concept, Multi-Center, Randomized, Double-Blind, Parallel, Placebo-Controlled Study of Zonisamide Sustained Release (SR) 360 mg versus Placebo in the Prevention of Weight Gain Associated with Olanzapine Therapy for Psychosis

Otsuka: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of XXX-XXXXX as Adjunctive Therapy in the Treatment of Patients with Major Depressive Disorder.

Otsuka: A 52-Week, Multicenter, Randomized,Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of Aripiprazole (XXX-XXXXX) as Maintenance Treatment in Patients with Schizophrenia.

Pfizer: A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Sequential Trial of Ziprasidone as Monotherapy for Major Depressive Disorder.